• PDR Search

    Required field
  • Advertisement
  • Stendra


    Phosphodiesterase type 5 inhibitor




    Treatment of erectile dysfunction (ED).


    Adults: Initial: 100mg PRN, 30 min before sexual activity. Titrate: May decrease to 50mg or increase to max of 200mg based on individual efficacy and tolerability. Max Frequency: QD. Use lowest effective dose. Sexual stimulation is required for response to treatment. Patients Stable on α-Blocker: Initial: 50mg. Concomitant Moderate CYP3A4 Inhibitors (eg, Erythromycin, Amprenavir, Diltiazem): Max: 50mg/24 hrs.


    Oral route. Take with or without food.


    Tab: 50mg, 100mg, 200mg


    Concomitant use (regularly and/or intermittently) with organic nitrates.


    In a patient who has taken avanafil, where nitrate administration is necessary, allow at least 12 hrs to elapse after the last dose of therapy before considering nitrate administration; only administer under close medical supervision with appropriate hemodynamic monitoring. Potential for cardiac risk during sexual activity in patients with preexisting cardiovascular (CV) disease; avoid if sexual activity is inadvisable due to underlying CV status. Patients with left ventricular outflow obstruction (eg, aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of BP may be sensitive to therapy. Has vasodilatory properties resulting in transient decreases in sitting BP. Not recommended in patients with myocardial infarction, stroke, life-threatening arrhythmia, or coronary revascularization within the last 6 months; or with resting hypotension (BP <90/50 mmHg) or HTN (BP >170/100 mmHg), unstable angina, angina with sexual intercourse, NYHA Class 2 or greater congestive heart failure, or hereditary degenerative retinal disorders including retinitis pigmentosa. Prolonged erection >4 hrs and priapism reported; caution with anatomical deformation of the penis (eg, angulation, cavernosal fibrosis, Peyronie's disease), or conditions that may predispose to priapism (eg, sickle cell anemia, multiple myeloma, leukemia). Non-arteritic anterior ischemic optic neuropathy rarely reported; d/c if sudden loss of vision in 1 or both eyes occurs. Sudden decrease or loss of hearing that may be accompanied by tinnitus or dizziness reported; d/c if this occurs. Avoid in patients with severe renal disease, on renal dialysis, or with severe hepatic disease.


    Headache, flushing, nasopharyngitis, nasal congestion, back pain, upper respiratory infection, ECG abnormal.


    See Contraindications and Dosage. Not recommended with other PDE-5 inhibitors or ED therapy combinations. Not recommended with CYP inducers. Caution with α-blockers; may augment BP-lowering effect of α-blockers and other antihypertensives. May increase the risk of orthostatic signs/symptoms with substantial alcohol consumption. Do not use with strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, clarithromycin, nefazodone). Increased levels with moderate CYP3A4 inhibitors and other CYP3A4 inhibitors (eg, grapefruit juice). May increase levels of desipramine or omeprazole. May affect rosiglitazone levels. Amlodipine may increase levels and prolong T1/2. May decrease amlodipine levels. May potentiate the antiaggregatory effect of sodium nitroprusside.


    Category C, safety not known in nursing.


    PDE-5 inhibitor; enhances effect of nitric oxide, which activates the enzyme guanylate cyclase resulting in increased levels of cGMP, producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.


    Absorption: Rapid; (fasted) Tmax=30-45 min (median). Distribution: Plasma protein binding (99%). Metabolism: Liver (extensive); CYP3A4 (major), CYP2C (minor); M4 and M16 (major circulating metabolites). Elimination: Feces (62% metabolites), urine (21% metabolites); T1/2=5 hrs.


    Assess for hypersensitivity to the drug, CV disease, left ventricular outflow obstruction, hereditary degenerative retinal disorders, anatomical deformation of the penis, conditions that predispose to priapism, potential underlying causes of ED, renal/hepatic impairment, any other conditions where treatment is contraindicated/cautioned, and possible drug interactions. Obtain baseline BP.


    Monitor for hypersensitivity reactions, priapism, changes in vision/hearing, and other adverse reactions.


    Instruct to take ud and that sexual stimulation is required for an erection to occur. Inform about the contraindication of avanafil with regular and/or intermittent use of organic nitrates; instruct patients who experience anginal chest pain after taking medication to seek immediate medical attention. Inform patients with preexisting CV risk factors of the potential cardiac risk of sexual activity; advise patients who experience symptoms upon initiation of sexual activity to refrain from further sexual activity and seek immediate medical attention. Advise to contact prescribing physician if new medications that may interact with therapy are prescribed by another healthcare provider. Instruct to seek emergency medical attention if erection persists >4 hrs; inform that priapism, if not treated promptly, may result in irreversible erectile tissue damage. Instruct to d/c and seek medical attention in the event of sudden loss of vision in 1 or both eyes or if a sudden decrease or loss of hearing that may be accompanied by tinnitus and dizziness occurs. Inform that substantial alcohol consumption (eg, >3 units) in combination with medication may increase the potential for orthostatic signs/symptoms. Inform that drug does not protect against sexually transmitted diseases (STDs); counsel about protective measures necessary to guard against STDs, including HIV.


    20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). Protect from light.